JP2015506355A5 - - Google Patents

Download PDF

Info

Publication number
JP2015506355A5
JP2015506355A5 JP2014549480A JP2014549480A JP2015506355A5 JP 2015506355 A5 JP2015506355 A5 JP 2015506355A5 JP 2014549480 A JP2014549480 A JP 2014549480A JP 2014549480 A JP2014549480 A JP 2014549480A JP 2015506355 A5 JP2015506355 A5 JP 2015506355A5
Authority
JP
Japan
Prior art keywords
alkyl
group
heterocyclyl
substituted
carbocyclyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014549480A
Other languages
English (en)
Japanese (ja)
Other versions
JP6130399B2 (ja
JP2015506355A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2012/077027 external-priority patent/WO2013098375A1/en
Publication of JP2015506355A publication Critical patent/JP2015506355A/ja
Publication of JP2015506355A5 publication Critical patent/JP2015506355A5/ja
Application granted granted Critical
Publication of JP6130399B2 publication Critical patent/JP6130399B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014549480A 2011-12-30 2012-12-28 新規アゼチジン誘導体、医薬組成物およびそれらの使用 Expired - Fee Related JP6130399B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11196170 2011-12-30
EP11196170.2 2011-12-30
PCT/EP2012/077027 WO2013098375A1 (en) 2011-12-30 2012-12-28 New azetidine derivatives, pharmaceutical compositions and uses thereof

Publications (3)

Publication Number Publication Date
JP2015506355A JP2015506355A (ja) 2015-03-02
JP2015506355A5 true JP2015506355A5 (enExample) 2016-02-25
JP6130399B2 JP6130399B2 (ja) 2017-05-17

Family

ID=47553036

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014549480A Expired - Fee Related JP6130399B2 (ja) 2011-12-30 2012-12-28 新規アゼチジン誘導体、医薬組成物およびそれらの使用

Country Status (13)

Country Link
US (1) US8623860B2 (enExample)
EP (1) EP2797884B1 (enExample)
JP (1) JP6130399B2 (enExample)
KR (1) KR20140115307A (enExample)
CN (1) CN104093705A (enExample)
AU (1) AU2012360797A1 (enExample)
BR (1) BR112014015845A8 (enExample)
CA (1) CA2861013A1 (enExample)
EA (1) EA201400771A1 (enExample)
IL (1) IL232914A0 (enExample)
MX (1) MX2014007897A (enExample)
PH (1) PH12014501514A1 (enExample)
WO (1) WO2013098375A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2707361T1 (sl) 2011-05-10 2017-12-29 Gilead Sciences, Inc. Zlite heterociklične spojine kot modulatorji natrijevega kanala
NO3175985T3 (enExample) 2011-07-01 2018-04-28
TWI549944B (zh) 2011-07-01 2016-09-21 吉李德科學股份有限公司 作為離子通道調節劑之稠合雜環化合物
WO2014061693A1 (ja) * 2012-10-17 2014-04-24 塩野義製薬株式会社 新規非芳香族炭素環又は非芳香族複素環誘導体
US20160220557A1 (en) 2013-09-12 2016-08-04 Pfizer Inc. Use of acetyl-coa carboxylase inhibitors for treating acne vulgaris
CN103483273B (zh) * 2013-09-12 2015-11-25 浙江工业大学 6-甲基-5-氟-2,4-嘧啶二胺类化合物及其制备与应用
US10150728B2 (en) 2013-10-17 2018-12-11 Shionogi & Co., Ltd. Alkylene derivatives
AU2015229188A1 (en) 2014-03-13 2016-09-29 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods for increasing CFTR activity
WO2015138934A1 (en) 2014-03-13 2015-09-17 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods for increasing cftr activity
EP3157917B1 (en) 2014-06-19 2020-03-18 Proteostasis Therapeutics, Inc. Compounds, compositions and methods of increasing cftr activity
CA2971855A1 (en) 2014-12-23 2016-06-30 Proteostasis Therapeutics, Inc. Derivatives of 5-(hetero)arylpyrazol-3-carboxylic amide or 1-(hetero)aryltriazol-4-carboxylic amide useful for the treatment of inter alia cystic fibrosis
WO2016105468A1 (en) 2014-12-23 2016-06-30 Proteostasis Therapeutics, Inc. Derivatives of 3-heteroarylisoxazol-5-carboxylic amide useful for the treatment of inter alia cystic fibrosis
MA41253A (fr) 2014-12-23 2017-10-31 Proteostasis Therapeutics Inc Composés, compositions et procédés pour augmenter l'activité du cftr
WO2016105477A1 (en) 2014-12-23 2016-06-30 Proteostasis Therapeutics, Inc Derivatives of 5-phenyl- or 5-heteroarylthiazol-2-carboxylic amide useful for the treatment of inter alia cystic fibrosis
EP3325474A1 (en) 2015-07-24 2018-05-30 Proteostasis Therapeutics, Inc. Compounds, compositions and methods of increasing cftr activity
JP6929276B2 (ja) 2015-10-06 2021-09-01 プロテオステイシス セラピューティクス,インコーポレイテッド 化合物、医薬的に許容される塩又はその立体異性体及び医薬組成物
US10662207B2 (en) 2016-04-07 2020-05-26 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods for modulating CFTR
WO2017223188A1 (en) 2016-06-21 2017-12-28 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods for increasing cftr activity
CN110776504B (zh) * 2019-11-29 2021-07-30 扬州工业职业技术学院 一种苯异噁唑乙氧基环丁胺衍生物及其制备方法与应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1478437B1 (en) 2002-02-27 2005-08-31 Pfizer Products Inc. Acc inhibitors
DE102005055726A1 (de) 2005-11-23 2007-08-30 Sanofi-Aventis Deutschland Gmbh Hydroxy-substituierte Diphenylazetidinone, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
MX2008008337A (es) 2005-12-21 2008-09-03 Schering Corp Fenoxipiperidinas y sus analogos utiles como antagonistas de histamina h3.
JP2009539884A (ja) * 2006-06-12 2009-11-19 メルク フロスト カナダ リミテツド ステアロイル−コエンザイムaデルタ−9デサチュラーゼのインヒビターとしてのアゼチジン誘導体
US20110183958A1 (en) 2008-10-17 2011-07-28 Merck Frosst Canada Ltd. Azetidine derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase
US20100280067A1 (en) 2009-04-30 2010-11-04 Pakala Kumara Savithru Sarma Inhibitors of acetyl-coa carboxylase
UA108102C2 (uk) 2010-04-27 2015-03-25 Біциклічні похідні і їх застосування як інгібіторів асс
MX2012013130A (es) * 2010-05-13 2013-04-11 Amgen Inc Compuestos heterociclicos de nitrogeno utiles como inhibidores de pde10.

Similar Documents

Publication Publication Date Title
JP2015506355A5 (enExample)
CN105745206B (zh) 用于治疗疾病的葡萄糖神经酰胺合成酶抑制剂
JP6648137B2 (ja) ヘテロ環式誘導体およびその使用
EP3083639B1 (en) Cyclic sulfone and sulfoximine analogs and uses thereof
JP4722851B2 (ja) キノリンカリウムチャネル阻害剤
JP4719151B2 (ja) イソキノリノンカリウムチャネル阻害剤
RU2013149174A (ru) Новое имидазооксазиновое соединение или его соль
JP2015500856A5 (enExample)
AU2012361581B2 (en) Effect potentiator for antitumor agents
RU2012104700A (ru) Азабициклосоединение и его соль
CA3027498A1 (en) Cxcr4 inhibitors and uses thereof
RU2012129168A (ru) Производные оксазина
RU2010126105A (ru) Производные пиридина, замещенные гетероциклическим кольцом и фосфоноксиметильной группой, и содержащие их противогрибковые средства
JP2015503540A5 (enExample)
RS54339B1 (sr) Novi antimalarijski agensi
He et al. Synthesis and biological evaluation of novel pyrazoline derivatives as potent anti-inflammatory agents
JP2013509392A5 (enExample)
RU2002131885A (ru) Антраниламиды и их применение в качестве лекарственных средств
RU2012108423A (ru) Ацилгуанидиновые производные с азотсодержащим циклом
JP2014516070A5 (enExample)
AU2009335221A1 (en) Toluidine sulfonamides and their use
JP2013540714A5 (enExample)
CA2626767A1 (en) Heterocyclic substituted pyridine derivatives and antifungal agent containing same
JP2015500267A5 (enExample)
EP4180429A1 (en) Pyrimidinone derivative, and preparation method therefor and use thereof against mycobacterium tuberculosis infection